OmniStar Financial Group Inc. Reduces Stock Holdings in Eli Lilly And Co (NYSE:LLY)

OmniStar Financial Group Inc. trimmed its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 7.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,120 shares of the company’s stock after selling 400 shares during the quarter. OmniStar Financial Group Inc.’s holdings in Eli Lilly And Co were worth $567,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Thoroughbred Financial Services LLC grew its stake in Eli Lilly And Co by 11,124.4% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 854,403 shares of the company’s stock valued at $85,440,000 after purchasing an additional 846,791 shares during the last quarter. Geode Capital Management LLC grew its stake in Eli Lilly And Co by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 13,108,002 shares of the company’s stock valued at $1,514,582,000 after purchasing an additional 830,689 shares during the last quarter. Bessemer Group Inc. grew its stake in Eli Lilly And Co by 2,354.5% during the 2nd quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock valued at $63,096,000 after purchasing an additional 546,307 shares during the last quarter. Goelzer Investment Management Inc. grew its stake in Eli Lilly And Co by 1,345.5% during the 1st quarter. Goelzer Investment Management Inc. now owns 312,151 shares of the company’s stock valued at $40,505,000 after purchasing an additional 290,557 shares during the last quarter. Finally, Schafer Cullen Capital Management Inc grew its stake in Eli Lilly And Co by 30.3% during the 2nd quarter. Schafer Cullen Capital Management Inc now owns 1,030,446 shares of the company’s stock valued at $111,587,000 after purchasing an additional 239,590 shares during the last quarter. Hedge funds and other institutional investors own 79.44% of the company’s stock.

Several analysts have weighed in on the company. TheStreet downgraded Eli Lilly And Co from a “b+” rating to a “c+” rating in a research note on Thursday, May 9th. Cantor Fitzgerald reiterated a “buy” rating and set a $143.00 price target on shares of Eli Lilly And Co in a research note on Tuesday, April 30th. Barclays reiterated a “buy” rating and set a $140.00 price target on shares of Eli Lilly And Co in a research note on Sunday, April 14th. Goldman Sachs Group assumed coverage on Eli Lilly And Co in a research note on Tuesday, May 28th. They set a “buy” rating and a $135.00 price target on the stock. Finally, Zacks Investment Research downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Tuesday, May 21st. Nine equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $123.49.

In other Eli Lilly And Co news, CFO Joshua L. Smiley purchased 426 shares of Eli Lilly And Co stock in a transaction that occurred on Wednesday, June 5th. The stock was bought at an average price of $118.03 per share, with a total value of $50,280.78. Following the acquisition, the chief financial officer now owns 30,410 shares of the company’s stock, valued at approximately $3,589,292.30. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Michael J. Harrington sold 16,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $116.72, for a total value of $1,867,520.00. Following the completion of the transaction, the vice president now directly owns 110,300 shares of the company’s stock, valued at approximately $12,874,216. The disclosure for this sale can be found here. 0.11% of the stock is owned by corporate insiders.

Shares of LLY traded down $0.20 during mid-day trading on Friday, reaching $113.77. The company had a trading volume of 2,665,061 shares, compared to its average volume of 4,391,698. Eli Lilly And Co has a 52-week low of $101.27 and a 52-week high of $132.13. The company has a quick ratio of 0.85, a current ratio of 1.13 and a debt-to-equity ratio of 4.98. The firm has a market capitalization of $107.28 billion, a PE ratio of 20.50, a P/E/G ratio of 1.96 and a beta of 0.19. The company has a 50 day moving average price of $110.86.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, July 30th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The firm had revenue of $5.64 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the business earned $1.48 earnings per share. The company’s revenue was up .9% compared to the same quarter last year. Analysts anticipate that Eli Lilly And Co will post 5.72 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $0.645 dividend. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.27%. Eli Lilly And Co’s payout ratio is 46.49%.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: How do CD ladders protect against rising interest rates?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.